PET/MRI Comparable to PET/CT in Staging Lung Cancer
PET/MR imaging offers comparable diagnostic image quality and tumor delineation in staging of lung cancer to PET/CT - with less radiation exposure.
PET plus MR imaging offers comparable diagnostic image quality and tumor delineation in staging of lung cancer to PET plus CT - with less radiation exposure to the patient, researchers reported in a study published in the journal Radiology.
Researchers from Eberhard-Karls University in Tübingen, Germany, studied 10 patients who were suspected to have or were diagnosed with bronchial carcinoma. The patients, aged 38 to 73, underwent fluorine 18 fluorodeoxyglucose (FDG) PET/CT, followed immediately by whole-body MR/PET imaging with a new hybrid whole-body system (3.0-T MR imager with integrated PET system).
Upon review of the results of the MR/PET, the researchers found nine of the 10 lesions showed pronounced FDG uptake. One lesion was morphologically suspicious for CT and MR imaging, but showed no FDG uptake.
Tumor-to-liver ratios were also calculated and compared between the two examinations. There was a significant correlation regarding the tumor-to-liver ratio with identical TNM scores for seven patients.
“MR/PET imaging of the lung is feasible and provides diagnostic image quality in the assessment of pulmonary masses,” the authors wrote. “Similar lesion characterization and tumor stage were found in comparing PET/CT and MR/PET images in most patients.”
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
